(secondQuint)Allogeneic CART-33 for Relapsed/Refractory CD33+ AML.

 The relapsed and/or refractory AML patients will receive infusions of allogeneic CART-33 within 1 week after chemotherapy.

 The re-induction chemotherapy regimen was primarily idarubicin and cytarabine, and no graft-versus-host disease (GVHD) prevention was conducted pre- and post- therapy.

.

 Allogeneic CART-33 for Relapsed/Refractory CD33+ AML@highlight

The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 33 (CD33)-directed chimeric antigen receptor modified T cells (CART-33) infusions in patients with relapsed / refractory acute myeloid leukemia (AML).

